

Ref: FOI/GS/ID 6146

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

08 July 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Prescribing in Ophthalmology.

You asked:

1. *Within your trust how many **intra-vitreous injections/implants** of each of the following drugs have been used in the four-month period from January to April 2020:*

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab

2. *If your trust is able to identify **intra-vitreous injections/implants** by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions:*

Wet Age Related Macular Degeneration (wAMD)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab

Diabetic Macular Oedema (DMO)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone
Fluocinolone
Ranibizumab
Retinal Vein Occlusion - Central (CRVO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Retinal Vein Occlusion - Branch (BRVO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab

Trust response:

Figures for January to April 2020 inclusive							
Drug	Abicipar Pegol	Aflibercept	Bevacizumab	Brolucizumab	Dexamethasone	Fluocinolone	Ranibizumab
Total Dispensed	0	1463	76	0	86	2	1132
WAMD	0	1038	data not available	0	0	0	600
DMO	0	261	data not available	0	26	1	271
CRVO	0	78	data not available	0	22	0	113
BRVO	0	82	data not available	0	17	0	137
MCNV	0	0	data not available	0	0	0	0